Topic summary

What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold?

Compounds › Retatrutide randomised trial effect size TRIUMPH programme retatrutide Solved

This is a generated summary. It shows the 7 most-liked posts from a topic of 48, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

desiccant_notesTL2Member9 Feb 2026#1

Asking directly, because I could not find a straight answer: What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold?

An honest uncertainty about TRIUMPH rather than a disguised assertion.

I do not know the answer and I have not been able to find one. What I have is the shape of the question, which may be worth more than my guess at the answer.

33 likes 6mo

integrator_traceTL2Member Solution23 Feb 2026 · edited#3

Picking up post #2: that is the part I would want checked first.

Summarising the TRIUMPH thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.

7 likes 5mo

n.kirchnerTL210 Mar 2026#6

No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.

I checked the source rather than the summary, and they differ.

25 likes 5mo

h.nwosuTL219 Apr 2026#16

TRIUMPH is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.

32 likes 3mo

c.boatengTL230 Apr 2026#19

Post #15 describes the usual case. This is about the unusual one.

Since TRIUMPH keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.

25 likes 3mo

j.marchettiTL27 May 2026#21

n.kirchner, post #6: No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet. I checked the source rather than the summary, and they differ. Go to post

The useful distinction on TRIUMPH is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.

31 likes in reply to #6 3mo

c.tullochTL211 Jul 2026#42

mira.patel, post #20: Adding the measurement that post #19 says would settle it. Whether triple agonism is additive or synergistic is an open question and the published work does not answer it. A phase 2 trial without a dual-agonist comparator arm cannot distinguish the two. Go to post

Speaking only to TRIUMPH as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.

29 likes in reply to #20 17d

Read the full topic (48 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on Compounds › Retatrutide preprint retatrutide TRIUMPH programme randomised trial Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. The question about…	+3	7	1k	2mo
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Compounds › Retatrutide retatrutide randomised trial effect size preprint Solved Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Writing it up because I had to work it out twice and would rather nobody else did. A methods question rather than a substantive…	+10	14	8.4k	16h
Second pass at: Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a small dataset on Triple agonism. It is…	+114	120	1.4k	10mo
Why retatrutide discussion here is more cautious than elsewhere — one year on Compounds › Retatrutide TRIUMPH programme effect size preprint retatrutide Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Two things I would like separated before anyone answers on…	+92	97	3.6k	20h
Second pass at: Retatrutide dose escalation in the published trials Compounds › Retatrutide retatrutide randomised trial preprint Under review Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Retatrutide…	+115	125	30k	2y

Related topics — sharing the tags randomised trial, effect size, TRIUMPH programme

Topic	Participants	Replies	Views	Activity
What we do not know about retatrutide, listed explicitly Compounds › Retatrutide retatrutide effect size preprint TRIUMPH programme The question in the title: What we do not know about retatrutide, listed explicitly I will give what I have already checked below so nobody repeats it. Setting out what I think I know about this compound and…	+106	113	4.8k	17mo
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Compounds › Oral incretins randomised trial orforglipron PIONEER programme Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on Dose…	+48	52	59k	18mo
Comparing the STEP programme populations: who was actually enrolled — the long version Compounds › Semaglutide STEP programme randomised trial type 2 diabetes On the subject in the title: Comparing the STEP programme populations: who was actually enrolled — the long version Working notes rather than a conclusion. A narrow question about Comparing the STEP programme…		4	7.7k	11mo
Revisiting: What pooling buys you and what it destroys Evidence › Meta-analyses heterogeneity effect size publication bias Solved On the subject in the title: Revisiting: What pooling buys you and what it destroys Working notes rather than a conclusion. Pooling buys — I have the observation and I do not trust my interpretation of it, so…	+97	107	4k	19h
Follow-up: Open-label extensions: what survives and what does not Evidence › Trials open label intention to treat surrogate endpoints estimand Solved Open-label extensions: what survives and what does not — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin Open-label extensions down and I want to set…	+22	26	397	16mo